Lyndi Rice, Ph.D.
Team Leader of
Cancer Signaling and Cell Cycle

Dr. Lyndi Rice received her Ph.D. from Drexel University College of Medicine in 2005 where she studied the role of protein phosphastase 2A (PP2A) in cell signaling during pre-meiotic DNA replication in the yeast model system, Saccharomyces cerevisiae. Dr. Rice then completed her post-doctoral research at the Wistar Institute, where she focused on gene silencing via chromatin remodeling and the incorporation of histones into the HSV-1 viral genome during its replication. In addition, Dr. Rice is an adjunct assistant faculty member at Rider University. In 2007, she joined Medical Diagnostic Laboratories LLC, where she initiated studies examining the role of PP2A in cholesterol metabolism and sterol-dependent gene induction. This work has led to several studies in mouse models, which are designed to validate potential biomarkers for metabolic diseases.

Since the inception of the Cancer Signaling and Cell Cycle team, Dr. Rice has studied the role of PP2A in tumorigenesis and cancer progression and has continued this research since joining Venenum Biodesign LLC. Additionally, her team is investigating the transcriptional regulation and post-translational modifications of a novel oncoprotein and has identified a role in cell proliferation and tumorigenesis for a protein known only to be involved in cholesterol metabolism. These projects involve exciting basic research with the ultimate goals of identifying novel biomarkers for urogenital cancers and drug target validation for cancer therapeutics. Currently, we are developing an ultra-high throughput screen for one of our validated targets in collaboration with members of UHTS.